ログイン

Urology Pharm

Urology Pharm
68問 • 2年前
  • Two Clean Queens
  • 通報

    問題一覧

  • 1

    PDE-5 Inhibitors

    Sidenadil, Vardenafil, Tadalafil, Avanafil

  • 2

    N.O. activates guanylyl --> forms cGMP from guanosine triphosphate. cGMP causes smooth muscle relaxation through a reduction in intracellular calcium concentration. The duration of action of cGMP is controlled by phosphodiesterase (PDE). Sildenafil, Vardenafil, Tadalafil, and Avanafil inhibit PDE-5 (isozyme responsible for degradation of cGMP in the corpus cavernosum). Inhibition of PDE-5 prevents degradation of cGMP thereby increasing blood flow during sexual stimulation.

    Mechanism of action for PDE-5 Inhibitors

  • 3

    Should be taken 1 hr prior to sex and last for up to 4 hrs, and absorption is delayed by high fat meal.

    Sildenafil and Vardenafil

  • 4

    This drug(s) is available as a ODT which is not affected by a high fat meal, and should be placed under the tongue without water

    Vardenafil

  • 5

    _____ has a higher bioavailability than _____ so the products are not interchangeable

    Vardenafil ODT; Vardenafil-coated oral tablet

  • 6

    Has a slower half onset of action and half-life than others in its class (18 hrs), so it is daily dosing with results lasting 36 hours. Absorption not impacted by food. Timing less of an issue due to its long duration.

    Tadalafil

  • 7

    Quickest onset of action (30-45 mins)

    Avanafil

  • 8

    Metabolized by CYP3A4

    PDE-5 Inhibitors

  • 9

    Contraindicated in severe renal impaiment?

    Avanafil and daily dose Tadalafil

  • 10

    Contraindicated with with organic nitrates (NO or isosorbide)

    PDE5-Inhibitors

  • 11

    Should be used with caution with alpha-adrenergic antagonists

    PDE-5 Inhibitors

  • 12

    Contraindicated with Dronedarone and Fluconazole (risk of QT prolongation)

    Vardenafil

  • 13

    Adverse Drug Effects – (most common) headache, flushing, dyspepsia, and nasal congestion; color vision changes that are dose dependent (disruption of PDE-6), sudden hearing loss (changes in sinus pressure during vasodilation); cardiac risk associated with sexual activity; priapism.

    PDE-5 Inhibitors

  • 14

    Adverse effects - does not cause changes in color vision like other drugs in its class; associated with back pain and myalgias (inhibition of PDE-11);

    Tadalfil

  • 15

    Exacerbate hypotensive activity of NO and alpha-adrenergic antagonists, interact with inhibitors of CYP3A4, and some can exacerbate the effects of drugs knowns to prolong QT interval

    Drug-drug interactions of PDE-5 Inhibitors

  • 16

    Dosage adjustments of these PDE-5 Inhibitors are recommended in patients with mild to moderate hepatic dysfunction.

    Sildenafil, Vardenafil, and Tadalafil

  • 17

    These PDE-5 Inhibitor doses should be reduced in severe renal dysfunction

    Sildenafil and Tadalafil

  • 18

    Use caution in patients with a history of or risk factors for CV disease

    PGE-5 Inhibitors

  • 19

    Do not use more than once per day for ED treatment

    PDE-5 Inhibitors

  • 20

    Exacerbate hypotensive activity of alpha-adrenergic antagonists and should be used with caution. Patients should be placed on a stable dose of alpha-adrenergic antagonists prior to being placed on this drug, and should be started at the lowest dose

    PDE-5 Inhibitors

  • 21

    Use caution when prescribing this drug with other drugs that prolong QT interval

    Vardenafil

  • 22

    May need to adjust doses of ________ when combining with drugs that are known inhibitors of CYP3A4 (Clarithromycin and Ritonavir)

    PDE-5 inhibitors

  • 23

    Prostaglandin E1 (PGE1) Drug Examples

    Alprostadil

  • 24

    Allows for relaxation of smooth muscle in the corpus cavernosum by an unknown mechanism, but it is believed that increases concentrations of cAMP within the cavernosal tissue resulting in protein kinase activation allowing trabecular smooth muscle relaxation and dilation of cavernosal arteries, increased blood flow to the erection chamber compresses venous blood outflow so that blood is entrapped and erection may occur

    Prostaglandin E1 (PGE1)

  • 25

    Systemic absorption is minimal, but if it is absorbed it is quickly metabolized. Onset is 2-25 minutes by injection causing an erection lasing for approximately 30-60 minutes.

    Pharmacokinetics of Prostaglandin E1 (PGE1)

  • 26

    They are rare since it is not systemically absorbed. However, hypotension and headache are possible since PGE-1 is a vasodilator. Bleeding from injection site is rare. Hematoma, ecchymosis, and rash from injection site is possible but rare. Priapism may occur.

    Adverse Drug Effects of Prostaglandin E1 (PGE1)

  • 27

    Terazosin, Doxazosin, Tamsulosin, Alfuzosin, and Silodosin

    Alpha-adrenergic antagonists

  • 28

    Selective competitive blockers of the alpha receptors (1A and 1B) causing prostatic smooth muscle relaxation, which improves urine flow. Doxazosin, Terazosin, and Alfuzosin block alpha (1A and 1B) receptors and decrease PVR and arterial BP, whereas Tamsulosin and Silodosin block alpha-1A receptors only and have less effect on BP because they are more selective.

    Mechanism of Action of Alpha-adrenergic antagonists

  • 29

    Pharmacokinetics for Alpha-adrenergic antagonists

    Well absorbed by oral administration. Doxazosin, Afluzosin, Tamsulosin, and Silodosin are metabolized through the cytochrome P450 system. Silodosin is a substrate for P-glycoprotein. Terazosin is metabolized by the liver but not through the CYP system. The half-life is 8-22 hours with a peak of 1-4 hours

  • 30

    Contraindications for Silodosin

    Severe Renal Dysfunction

  • 31

    Adverse Drug Effects of Alpha-adrenergic antagonists

    Dizziness, fatigue, nasal congestion, headache, drowsiness, orthostatic hypotension. Drugs that are selective for its receptor have an increased incidence of retrograde ejaculation or the ability to ejaculate. “Floppy Iris Syndrome” during cataract eye surgery.

  • 32

    Drugs that inhibit CYP3A4 and CYP2D6 (Verapamil and Dilitazem) may increase plasma concentrations of _______.

    Doxazosin, Alfuzosin, Tamsulosin, and Silodosin

  • 33

    Drugs that induce the CYP450 system (Carbamazepin, Phenytoin, and St. John’s Wart) may _____.

    Decrease plasma concentrations of Alpha-adrenergic antagonists

  • 34

    _______ may prolong QT interval so use caution with other drugs that prolong QT interval (class III anti-arrhythmics).

    Alfuzosin

  • 35

    Drugs that inhibit _____may increase Silodosin concentrations

    P-gp (cyclosproine)

  • 36

    ______should be administered with food. _______should be taken without food.

    Tamsulosin, Alfuzosin, and Silodosin; Doxazosin and Terazosin

  • 37

    ______ requires dosage adjustment in renal impairment

    Silodosin

  • 38

    5 alpha-reductase inhibitors

    Finasteride and Dutasteride

  • 39

    Mechanism of Action for 5 alpha-reductase inhibitors

    Inhibition of 5 alpha-reductase which converts testosterone to dihydrotestosterone (DHT). DHT is an androgen that stimulates prostate growth. By reducing DHT, the prostate shrinks, and urine flow improves, but in order to be effective the prostate must be enlarged. It takes several months for the drug to be effective. Both drugs can also treat alopecia.

  • 40

    Pharmacokinetis of 5 alpha-reductase inhibitors

    These drugs can be taken with food. Both drugs are highly protein bound and metabolized by the CYP450 system. The mean plasma elimination half-life of Finasteride is 6-16 hours, while the terminal elimination half-life of Dutasteride is 5 weeks once steady-state is achieved (typically after 6 months of therapy).

  • 41

    Decreased ejaculate and libido, ED, gynecomastia, and oligospermia. Both drugs are teratogenic can should not be handled by women of childbearing age or who are pregnant. Although they are metabolized by the CYP450 system, drug interactions are rare. Not recommended to use these drugs with testosterone since they inhibit conversion of testosterone to DHT.

    Adverse Drug Effects of 5 alpha-reductase inhibitors

  • 42

    Should be taken with alpha-blockers to relieve symptoms, and both drugs are available in a combo with an alpha-blocker

    5 alpha-reductase inhibitors

  • 43

    What produces the greatest reduction in BPH symptoms?

    Comination therapy (5-alpha reductase inhibitor + alpha-adrenergic antagonists)

  • 44

    A 68-year old man presents to his physician with complaints of inability to maintain an erection during sexual intercourse. He is diagnosed with ED and started on PDE-5 inhibitor. What is the mechanism of action in the treatment of ED?

    Block the degredation of cGMP in the corpus cavernosum

  • 45

    A patient who is taking a PDE-5 inhibitor for ED is diagnosed with angina. Which of the following antianginal medications would be of particular concern in this patient?

    Nitroglycerin

  • 46

    Which of the following statements most accurately describes Alprostadil in the treatement of ED?

    Used as an alternative for patients who are not candidates for oral therapies for ED

  • 47

    Which of the following enzymes or receptors does Tamsulosin block to aid in the treatment of BPH?

    Alpha-(a1) receptor

  • 48

    A patient is worried about starting a new medication to treat BPH beause he is very sensitive to side effects of medications. Which of the following alpha-1-adrenergic antagonists could be recommended because of a lower incidence of systemic side effects?

    Silodosin

  • 49

    A 74-year old patient presents to his PCP to discuss treatment for ED. His current medications include furosemide, isosorbide dinitrate, lisinopril, metformin, and metoprolol succinate. Which of the following would be the safest option for his ED?

    Alprostadil

  • 50

    A patient with BPH has been taking Finasteride for 6 weeks. He reports no improvement in symptoms of urinary frequency, hesitancy, and urgency. On physical exam, it is deterimined that his prostate is significantly enlarged. Which of the following is the best recommendation for this patient?

    Start Tamsulosin and continue Finasteride

  • 51

    A 70-year old man with BPH and has enlarged prostate continues to have urinary symptoms after an adequate trial of Tamsulosin. He is diagnosed with ED. Which medication can be used to treat both BPH and ED in this patient?

    Tadalafil

  • 52

    A patient who is currently being treated for ED with Tadalafil tells the physician that the medication takes too long to work. As such, he would like an alternative that has a faster onset of action. Which of the following PDE-5 inhibitors would be the most appropriate alternative of this patient?

    Avanafil

  • 53

    Which of the following is the CORRECT mechanism of action for Finasteride?

    Inhibits 5-alpha-reductase

  • 54

    Which agent [s] has/have a low likelihood of causing CV adverse effects in a patient with BPH who is also taken meds for HTN? 1. Alfuzosin [Uroxatrol] 2. Tamulosin [Flomax] 3. Finasteride [Proscar]

    2 and 3

  • 55

    Stimulation of muscarinic cholinergic receptors in the bladder muscle may be responsible for:

    Urge incontinence and bladder overactivity

  • 56

    Which of the following drugs in most appropriate for managing incontinence related to bladder overactivity?

    Oxybutynin

  • 57

    Which of the following distinguishes the phosphodiesterase type 5 [PDE-5] inhibitor Tadalafil [Cialis] from the other inhibitors Sildenafil [Viagra] and Vardenafil [Levitra]?

    Duration of Action

  • 58

    Which of the following is NOT a desired characteristic of a therapy for ED?

    Leads to a prolonged erection [>4 hours]

  • 59

    What is the MOA of the PDE-5 inhibitors?

    Enhance effect of nitric oxide

  • 60

    Your patient is taking a PGE-5 inhibitor for ED—he is diagnosed with angina. Which of the following medications would be of particular concern in this man?

    Isosorbide

  • 61

    Which of the following is TRUE regarding Finasteride [Proscar]?

    Associated with birth defects

  • 62

    Your patient is concerned about starting Terazosin because he is very sensitive to side effects of medications. Which of the following adverse effects would be most expected in this patient?

    Dizziness

  • 63

    Your patient is a 62 y/o female with UI, 6 weeks ago she began estrogen vaginal cream at bedtime and Kegel exercises—she says she is no better. She states she leaks whenever she is doing any activity—none when seated or recumbent. She has a history of HTN and she takes HCTZ to control her BP. What kind of UI are you treating?What is the most appropriate next step? What is the most important third step?

    Stress incontinence; Refer to urologist for biofeedback to assist with Kegel exercises; Refer to urologist for consideration of periurethral bulking agents

  • 64

    Doses of _____may need to be reduces in the presence of potent inhibitors of CYP34A (clarithromycin and ritonavir)

    PDE-5 Inhibitors

  • 65

    It is not ideal to use 5-Alpha Reductase Inhibitors with _____?

    Testosterone because the drugs inhibit the conversion of testosterone to DHT

  • 66

    Should be avoided in severe hepatic impairment

    PGE-5 Inhibitors

  • 67

    Verapamil and Dilitazem may increase plasma concentrations of _______.

    Doxazosin, Alfuzosin, Tamsulosin, and Silodosin

  • 68

    Carbamazepin, Phenytoin, and St. John’s Wart may _____.

    Decrease plasma concentrations of Doxasozin, Alfuzosin, Tamulosin, and Silodosin

  • Patho Renal

    Patho Renal

    Two Clean Queens · 100問 · 2年前

    Patho Renal

    Patho Renal

    100問 • 2年前
    Two Clean Queens

    Pathophysiology

    Pathophysiology

    Two Clean Queens · 100問 · 2年前

    Pathophysiology

    Pathophysiology

    100問 • 2年前
    Two Clean Queens

    Patho Immunology

    Patho Immunology

    Two Clean Queens · 34問 · 2年前

    Patho Immunology

    Patho Immunology

    34問 • 2年前
    Two Clean Queens

    Patho Hematology

    Patho Hematology

    Two Clean Queens · 100問 · 2年前

    Patho Hematology

    Patho Hematology

    100問 • 2年前
    Two Clean Queens

    Patho Hematology 2

    Patho Hematology 2

    Two Clean Queens · 76問 · 2年前

    Patho Hematology 2

    Patho Hematology 2

    76問 • 2年前
    Two Clean Queens

    Patho Respiratory

    Patho Respiratory

    Two Clean Queens · 100問 · 2年前

    Patho Respiratory

    Patho Respiratory

    100問 • 2年前
    Two Clean Queens

    Patho Respiratory 2

    Patho Respiratory 2

    Two Clean Queens · 54問 · 2年前

    Patho Respiratory 2

    Patho Respiratory 2

    54問 • 2年前
    Two Clean Queens

    Patho Cardiovascular

    Patho Cardiovascular

    Two Clean Queens · 100問 · 2年前

    Patho Cardiovascular

    Patho Cardiovascular

    100問 • 2年前
    Two Clean Queens

    Patho Cardiovascular 2

    Patho Cardiovascular 2

    Two Clean Queens · 56問 · 2年前

    Patho Cardiovascular 2

    Patho Cardiovascular 2

    56問 • 2年前
    Two Clean Queens

    Patho MSK

    Patho MSK

    Two Clean Queens · 52問 · 2年前

    Patho MSK

    Patho MSK

    52問 • 2年前
    Two Clean Queens

    Patho Acid Base

    Patho Acid Base

    Two Clean Queens · 35問 · 2年前

    Patho Acid Base

    Patho Acid Base

    35問 • 2年前
    Two Clean Queens

    Renal 2

    Renal 2

    Two Clean Queens · 10問 · 2年前

    Renal 2

    Renal 2

    10問 • 2年前
    Two Clean Queens

    Fluid Balance

    Fluid Balance

    Two Clean Queens · 43問 · 2年前

    Fluid Balance

    Fluid Balance

    43問 • 2年前
    Two Clean Queens

    Patho Endocrine

    Patho Endocrine

    Two Clean Queens · 100問 · 2年前

    Patho Endocrine

    Patho Endocrine

    100問 • 2年前
    Two Clean Queens

    Patho Endocrine 2

    Patho Endocrine 2

    Two Clean Queens · 42問 · 2年前

    Patho Endocrine 2

    Patho Endocrine 2

    42問 • 2年前
    Two Clean Queens

    Infections

    Infections

    Two Clean Queens · 58問 · 2年前

    Infections

    Infections

    58問 • 2年前
    Two Clean Queens

    Patho Shock

    Patho Shock

    Two Clean Queens · 31問 · 2年前

    Patho Shock

    Patho Shock

    31問 • 2年前
    Two Clean Queens

    GI

    GI

    Two Clean Queens · 100問 · 2年前

    GI

    GI

    100問 • 2年前
    Two Clean Queens

    GI 2

    GI 2

    Two Clean Queens · 18問 · 2年前

    GI 2

    GI 2

    18問 • 2年前
    Two Clean Queens

    Cancer

    Cancer

    Two Clean Queens · 54問 · 2年前

    Cancer

    Cancer

    54問 • 2年前
    Two Clean Queens

    Neuro

    Neuro

    Two Clean Queens · 94問 · 2年前

    Neuro

    Neuro

    94問 • 2年前
    Two Clean Queens

    Psychopathology

    Psychopathology

    Two Clean Queens · 20問 · 2年前

    Psychopathology

    Psychopathology

    20問 • 2年前
    Two Clean Queens

    Bone Pharm

    Bone Pharm

    Two Clean Queens · 77問 · 2年前

    Bone Pharm

    Bone Pharm

    77問 • 2年前
    Two Clean Queens

    Lifestyle Considerations Outline_Pharm

    Lifestyle Considerations Outline_Pharm

    Two Clean Queens · 97問 · 2年前

    Lifestyle Considerations Outline_Pharm

    Lifestyle Considerations Outline_Pharm

    97問 • 2年前
    Two Clean Queens

    Prescribing Basics Outline_Pharm

    Prescribing Basics Outline_Pharm

    Two Clean Queens · 23問 · 2年前

    Prescribing Basics Outline_Pharm

    Prescribing Basics Outline_Pharm

    23問 • 2年前
    Two Clean Queens

    Pharmacokinetics_Pharm

    Pharmacokinetics_Pharm

    Two Clean Queens · 31問 · 2年前

    Pharmacokinetics_Pharm

    Pharmacokinetics_Pharm

    31問 • 2年前
    Two Clean Queens

    Diabetes Pharm

    Diabetes Pharm

    Two Clean Queens · 100問 · 2年前

    Diabetes Pharm

    Diabetes Pharm

    100問 • 2年前
    Two Clean Queens

    Diabetes Pharm 2

    Diabetes Pharm 2

    Two Clean Queens · 41問 · 2年前

    Diabetes Pharm 2

    Diabetes Pharm 2

    41問 • 2年前
    Two Clean Queens

    Neuroendocrine Obesity Pharm

    Neuroendocrine Obesity Pharm

    Two Clean Queens · 100問 · 2年前

    Neuroendocrine Obesity Pharm

    Neuroendocrine Obesity Pharm

    100問 • 2年前
    Two Clean Queens

    Neuroendocrine Obesity Pharm 2

    Neuroendocrine Obesity Pharm 2

    Two Clean Queens · 43問 · 2年前

    Neuroendocrine Obesity Pharm 2

    Neuroendocrine Obesity Pharm 2

    43問 • 2年前
    Two Clean Queens

    Dermatology Pharm

    Dermatology Pharm

    Two Clean Queens · 106問 · 1年前

    Dermatology Pharm

    Dermatology Pharm

    106問 • 1年前
    Two Clean Queens

    Dermatology Pharm 2

    Dermatology Pharm 2

    Two Clean Queens · 24問 · 1年前

    Dermatology Pharm 2

    Dermatology Pharm 2

    24問 • 1年前
    Two Clean Queens

    Cardiac/Renal Pharm 1

    Cardiac/Renal Pharm 1

    Two Clean Queens · 100問 · 1年前

    Cardiac/Renal Pharm 1

    Cardiac/Renal Pharm 1

    100問 • 1年前
    Two Clean Queens

    Cardiac/Renal Pharm 2

    Cardiac/Renal Pharm 2

    Two Clean Queens · 100問 · 1年前

    Cardiac/Renal Pharm 2

    Cardiac/Renal Pharm 2

    100問 • 1年前
    Two Clean Queens

    Cardiac/Renal Pharm 3

    Cardiac/Renal Pharm 3

    Two Clean Queens · 86問 · 1年前

    Cardiac/Renal Pharm 3

    Cardiac/Renal Pharm 3

    86問 • 1年前
    Two Clean Queens

    Anticoagulants Pharm

    Anticoagulants Pharm

    Two Clean Queens · 46問 · 1年前

    Anticoagulants Pharm

    Anticoagulants Pharm

    46問 • 1年前
    Two Clean Queens

    Herbals

    Herbals

    Two Clean Queens · 48問 · 1年前

    Herbals

    Herbals

    48問 • 1年前
    Two Clean Queens

    N5220 Exam Pearls

    N5220 Exam Pearls

    Two Clean Queens · 100問 · 1年前

    N5220 Exam Pearls

    N5220 Exam Pearls

    100問 • 1年前
    Two Clean Queens

    DRIQ

    DRIQ

    Two Clean Queens · 67問 · 1年前

    DRIQ

    DRIQ

    67問 • 1年前
    Two Clean Queens

    Clinical Pearls Test 2

    Clinical Pearls Test 2

    Two Clean Queens · 76問 · 1年前

    Clinical Pearls Test 2

    Clinical Pearls Test 2

    76問 • 1年前
    Two Clean Queens

    Test 2 Seidel's Part I

    Test 2 Seidel's Part I

    Two Clean Queens · 94問 · 1年前

    Test 2 Seidel's Part I

    Test 2 Seidel's Part I

    94問 • 1年前
    Two Clean Queens

    Test 2 Seidel's Part II

    Test 2 Seidel's Part II

    Two Clean Queens · 98問 · 1年前

    Test 2 Seidel's Part II

    Test 2 Seidel's Part II

    98問 • 1年前
    Two Clean Queens

    NURS 5112 Exam Review Part 1

    NURS 5112 Exam Review Part 1

    Two Clean Queens · 66問 · 1年前

    NURS 5112 Exam Review Part 1

    NURS 5112 Exam Review Part 1

    66問 • 1年前
    Two Clean Queens

    NURS 5140 Exam 1 Review Part 1

    NURS 5140 Exam 1 Review Part 1

    Two Clean Queens · 100問 · 1年前

    NURS 5140 Exam 1 Review Part 1

    NURS 5140 Exam 1 Review Part 1

    100問 • 1年前
    Two Clean Queens

    NURS 5140 Exam 1 Review Application Part 1

    NURS 5140 Exam 1 Review Application Part 1

    Two Clean Queens · 100問 · 1年前

    NURS 5140 Exam 1 Review Application Part 1

    NURS 5140 Exam 1 Review Application Part 1

    100問 • 1年前
    Two Clean Queens

    NURS 5410 Exam 1 ApplicationPart 2

    NURS 5410 Exam 1 ApplicationPart 2

    Two Clean Queens · 50問 · 1年前

    NURS 5410 Exam 1 ApplicationPart 2

    NURS 5410 Exam 1 ApplicationPart 2

    50問 • 1年前
    Two Clean Queens

    Exam 2 NURS 5140

    Exam 2 NURS 5140

    Two Clean Queens · 8問 · 1年前

    Exam 2 NURS 5140

    Exam 2 NURS 5140

    8問 • 1年前
    Two Clean Queens

    NURS 5112 Exam 2 ChatGPT

    NURS 5112 Exam 2 ChatGPT

    Two Clean Queens · 90問 · 1年前

    NURS 5112 Exam 2 ChatGPT

    NURS 5112 Exam 2 ChatGPT

    90問 • 1年前
    Two Clean Queens

    Exam 3 NURS 5410 Anxiety

    Exam 3 NURS 5410 Anxiety

    Two Clean Queens · 66問 · 1年前

    Exam 3 NURS 5410 Anxiety

    Exam 3 NURS 5410 Anxiety

    66問 • 1年前
    Two Clean Queens

    Exam 3 NURS 5410 Pain

    Exam 3 NURS 5410 Pain

    Two Clean Queens · 44問 · 1年前

    Exam 3 NURS 5410 Pain

    Exam 3 NURS 5410 Pain

    44問 • 1年前
    Two Clean Queens

    Exam 3 NURS 5410 Sleep

    Exam 3 NURS 5410 Sleep

    Two Clean Queens · 72問 · 1年前

    Exam 3 NURS 5410 Sleep

    Exam 3 NURS 5410 Sleep

    72問 • 1年前
    Two Clean Queens

    NURS 5410 Exam 3 Quizzes

    NURS 5410 Exam 3 Quizzes

    Two Clean Queens · 25問 · 1年前

    NURS 5410 Exam 3 Quizzes

    NURS 5410 Exam 3 Quizzes

    25問 • 1年前
    Two Clean Queens

    Psychopharm Exam 1

    Psychopharm Exam 1

    Two Clean Queens · 71問 · 1年前

    Psychopharm Exam 1

    Psychopharm Exam 1

    71問 • 1年前
    Two Clean Queens

    Gero Psych Exam 1

    Gero Psych Exam 1

    Two Clean Queens · 62問 · 1年前

    Gero Psych Exam 1

    Gero Psych Exam 1

    62問 • 1年前
    Two Clean Queens

    Psychopharmacology Exam 2 (part 1)

    Psychopharmacology Exam 2 (part 1)

    Two Clean Queens · 19問 · 1年前

    Psychopharmacology Exam 2 (part 1)

    Psychopharmacology Exam 2 (part 1)

    19問 • 1年前
    Two Clean Queens

    Peds Psych Exam 2 (part 1)

    Peds Psych Exam 2 (part 1)

    Two Clean Queens · 19問 · 1年前

    Peds Psych Exam 2 (part 1)

    Peds Psych Exam 2 (part 1)

    19問 • 1年前
    Two Clean Queens

    Peds Psych Exam 2 (part 2)

    Peds Psych Exam 2 (part 2)

    Two Clean Queens · 50問 · 1年前

    Peds Psych Exam 2 (part 2)

    Peds Psych Exam 2 (part 2)

    50問 • 1年前
    Two Clean Queens

    Peds Psych Exam 2 (part 3)

    Peds Psych Exam 2 (part 3)

    Two Clean Queens · 67問 · 1年前

    Peds Psych Exam 2 (part 3)

    Peds Psych Exam 2 (part 3)

    67問 • 1年前
    Two Clean Queens

    Peds Psych Exam 2 (part 4)

    Peds Psych Exam 2 (part 4)

    Two Clean Queens · 20問 · 1年前

    Peds Psych Exam 2 (part 4)

    Peds Psych Exam 2 (part 4)

    20問 • 1年前
    Two Clean Queens

    Psychopharmacology Exam 2 (part 2)

    Psychopharmacology Exam 2 (part 2)

    Two Clean Queens · 80問 · 1年前

    Psychopharmacology Exam 2 (part 2)

    Psychopharmacology Exam 2 (part 2)

    80問 • 1年前
    Two Clean Queens

    Psychopharmacology Exam 2 (part 3)

    Psychopharmacology Exam 2 (part 3)

    Two Clean Queens · 46問 · 1年前

    Psychopharmacology Exam 2 (part 3)

    Psychopharmacology Exam 2 (part 3)

    46問 • 1年前
    Two Clean Queens

    Psychopharmacology Exam 2 (part 4)

    Psychopharmacology Exam 2 (part 4)

    Two Clean Queens · 22問 · 1年前

    Psychopharmacology Exam 2 (part 4)

    Psychopharmacology Exam 2 (part 4)

    22問 • 1年前
    Two Clean Queens

    Psychopharm Depressive Disorders

    Psychopharm Depressive Disorders

    Two Clean Queens · 86問 · 11ヶ月前

    Psychopharm Depressive Disorders

    Psychopharm Depressive Disorders

    86問 • 11ヶ月前
    Two Clean Queens

    Psychopharm Bipolar Disorder

    Psychopharm Bipolar Disorder

    Two Clean Queens · 58問 · 11ヶ月前

    Psychopharm Bipolar Disorder

    Psychopharm Bipolar Disorder

    58問 • 11ヶ月前
    Two Clean Queens

    Psychopharm Anxiety Disorders

    Psychopharm Anxiety Disorders

    Two Clean Queens · 32問 · 11ヶ月前

    Psychopharm Anxiety Disorders

    Psychopharm Anxiety Disorders

    32問 • 11ヶ月前
    Two Clean Queens

    Child Psych Anxiety

    Child Psych Anxiety

    Two Clean Queens · 56問 · 11ヶ月前

    Child Psych Anxiety

    Child Psych Anxiety

    56問 • 11ヶ月前
    Two Clean Queens

    Child Psych OCD/Gen Dysph

    Child Psych OCD/Gen Dysph

    Two Clean Queens · 34問 · 11ヶ月前

    Child Psych OCD/Gen Dysph

    Child Psych OCD/Gen Dysph

    34問 • 11ヶ月前
    Two Clean Queens

    Child Psych Eating Disorders 1

    Child Psych Eating Disorders 1

    Two Clean Queens · 49問 · 11ヶ月前

    Child Psych Eating Disorders 1

    Child Psych Eating Disorders 1

    49問 • 11ヶ月前
    Two Clean Queens

    Child Psych Eating Disorders 2

    Child Psych Eating Disorders 2

    Two Clean Queens · 14問 · 11ヶ月前

    Child Psych Eating Disorders 2

    Child Psych Eating Disorders 2

    14問 • 11ヶ月前
    Two Clean Queens

    Gero Mood Disorders

    Gero Mood Disorders

    Two Clean Queens · 19問 · 11ヶ月前

    Gero Mood Disorders

    Gero Mood Disorders

    19問 • 11ヶ月前
    Two Clean Queens

    Gero Anxiety Disorders

    Gero Anxiety Disorders

    Two Clean Queens · 13問 · 11ヶ月前

    Gero Anxiety Disorders

    Gero Anxiety Disorders

    13問 • 11ヶ月前
    Two Clean Queens

    Gero OCD & PTSD

    Gero OCD & PTSD

    Two Clean Queens · 15問 · 11ヶ月前

    Gero OCD & PTSD

    Gero OCD & PTSD

    15問 • 11ヶ月前
    Two Clean Queens

    Psychopharm Sleep

    Psychopharm Sleep

    Two Clean Queens · 34問 · 10ヶ月前

    Psychopharm Sleep

    Psychopharm Sleep

    34問 • 10ヶ月前
    Two Clean Queens

    Psychopharm ADHD

    Psychopharm ADHD

    Two Clean Queens · 20問 · 10ヶ月前

    Psychopharm ADHD

    Psychopharm ADHD

    20問 • 10ヶ月前
    Two Clean Queens

    Psychopharm Eating Disorders

    Psychopharm Eating Disorders

    Two Clean Queens · 6問 · 10ヶ月前

    Psychopharm Eating Disorders

    Psychopharm Eating Disorders

    6問 • 10ヶ月前
    Two Clean Queens

    Psychopharm Reward and Pleasure

    Psychopharm Reward and Pleasure

    Two Clean Queens · 32問 · 10ヶ月前

    Psychopharm Reward and Pleasure

    Psychopharm Reward and Pleasure

    32問 • 10ヶ月前
    Two Clean Queens

    Psychopharm Impulsivity/Compulsvity/Addiction

    Psychopharm Impulsivity/Compulsvity/Addiction

    Two Clean Queens · 7問 · 10ヶ月前

    Psychopharm Impulsivity/Compulsvity/Addiction

    Psychopharm Impulsivity/Compulsvity/Addiction

    7問 • 10ヶ月前
    Two Clean Queens

    Gero Exam 4 Review

    Gero Exam 4 Review

    Two Clean Queens · 81問 · 10ヶ月前

    Gero Exam 4 Review

    Gero Exam 4 Review

    81問 • 10ヶ月前
    Two Clean Queens

    Child Psych Sleep/Wake Disorders

    Child Psych Sleep/Wake Disorders

    Two Clean Queens · 58問 · 10ヶ月前

    Child Psych Sleep/Wake Disorders

    Child Psych Sleep/Wake Disorders

    58問 • 10ヶ月前
    Two Clean Queens

    Child Psych ODD/CD/SUD

    Child Psych ODD/CD/SUD

    Two Clean Queens · 49問 · 10ヶ月前

    Child Psych ODD/CD/SUD

    Child Psych ODD/CD/SUD

    49問 • 10ヶ月前
    Two Clean Queens

    問題一覧

  • 1

    PDE-5 Inhibitors

    Sidenadil, Vardenafil, Tadalafil, Avanafil

  • 2

    N.O. activates guanylyl --> forms cGMP from guanosine triphosphate. cGMP causes smooth muscle relaxation through a reduction in intracellular calcium concentration. The duration of action of cGMP is controlled by phosphodiesterase (PDE). Sildenafil, Vardenafil, Tadalafil, and Avanafil inhibit PDE-5 (isozyme responsible for degradation of cGMP in the corpus cavernosum). Inhibition of PDE-5 prevents degradation of cGMP thereby increasing blood flow during sexual stimulation.

    Mechanism of action for PDE-5 Inhibitors

  • 3

    Should be taken 1 hr prior to sex and last for up to 4 hrs, and absorption is delayed by high fat meal.

    Sildenafil and Vardenafil

  • 4

    This drug(s) is available as a ODT which is not affected by a high fat meal, and should be placed under the tongue without water

    Vardenafil

  • 5

    _____ has a higher bioavailability than _____ so the products are not interchangeable

    Vardenafil ODT; Vardenafil-coated oral tablet

  • 6

    Has a slower half onset of action and half-life than others in its class (18 hrs), so it is daily dosing with results lasting 36 hours. Absorption not impacted by food. Timing less of an issue due to its long duration.

    Tadalafil

  • 7

    Quickest onset of action (30-45 mins)

    Avanafil

  • 8

    Metabolized by CYP3A4

    PDE-5 Inhibitors

  • 9

    Contraindicated in severe renal impaiment?

    Avanafil and daily dose Tadalafil

  • 10

    Contraindicated with with organic nitrates (NO or isosorbide)

    PDE5-Inhibitors

  • 11

    Should be used with caution with alpha-adrenergic antagonists

    PDE-5 Inhibitors

  • 12

    Contraindicated with Dronedarone and Fluconazole (risk of QT prolongation)

    Vardenafil

  • 13

    Adverse Drug Effects – (most common) headache, flushing, dyspepsia, and nasal congestion; color vision changes that are dose dependent (disruption of PDE-6), sudden hearing loss (changes in sinus pressure during vasodilation); cardiac risk associated with sexual activity; priapism.

    PDE-5 Inhibitors

  • 14

    Adverse effects - does not cause changes in color vision like other drugs in its class; associated with back pain and myalgias (inhibition of PDE-11);

    Tadalfil

  • 15

    Exacerbate hypotensive activity of NO and alpha-adrenergic antagonists, interact with inhibitors of CYP3A4, and some can exacerbate the effects of drugs knowns to prolong QT interval

    Drug-drug interactions of PDE-5 Inhibitors

  • 16

    Dosage adjustments of these PDE-5 Inhibitors are recommended in patients with mild to moderate hepatic dysfunction.

    Sildenafil, Vardenafil, and Tadalafil

  • 17

    These PDE-5 Inhibitor doses should be reduced in severe renal dysfunction

    Sildenafil and Tadalafil

  • 18

    Use caution in patients with a history of or risk factors for CV disease

    PGE-5 Inhibitors

  • 19

    Do not use more than once per day for ED treatment

    PDE-5 Inhibitors

  • 20

    Exacerbate hypotensive activity of alpha-adrenergic antagonists and should be used with caution. Patients should be placed on a stable dose of alpha-adrenergic antagonists prior to being placed on this drug, and should be started at the lowest dose

    PDE-5 Inhibitors

  • 21

    Use caution when prescribing this drug with other drugs that prolong QT interval

    Vardenafil

  • 22

    May need to adjust doses of ________ when combining with drugs that are known inhibitors of CYP3A4 (Clarithromycin and Ritonavir)

    PDE-5 inhibitors

  • 23

    Prostaglandin E1 (PGE1) Drug Examples

    Alprostadil

  • 24

    Allows for relaxation of smooth muscle in the corpus cavernosum by an unknown mechanism, but it is believed that increases concentrations of cAMP within the cavernosal tissue resulting in protein kinase activation allowing trabecular smooth muscle relaxation and dilation of cavernosal arteries, increased blood flow to the erection chamber compresses venous blood outflow so that blood is entrapped and erection may occur

    Prostaglandin E1 (PGE1)

  • 25

    Systemic absorption is minimal, but if it is absorbed it is quickly metabolized. Onset is 2-25 minutes by injection causing an erection lasing for approximately 30-60 minutes.

    Pharmacokinetics of Prostaglandin E1 (PGE1)

  • 26

    They are rare since it is not systemically absorbed. However, hypotension and headache are possible since PGE-1 is a vasodilator. Bleeding from injection site is rare. Hematoma, ecchymosis, and rash from injection site is possible but rare. Priapism may occur.

    Adverse Drug Effects of Prostaglandin E1 (PGE1)

  • 27

    Terazosin, Doxazosin, Tamsulosin, Alfuzosin, and Silodosin

    Alpha-adrenergic antagonists

  • 28

    Selective competitive blockers of the alpha receptors (1A and 1B) causing prostatic smooth muscle relaxation, which improves urine flow. Doxazosin, Terazosin, and Alfuzosin block alpha (1A and 1B) receptors and decrease PVR and arterial BP, whereas Tamsulosin and Silodosin block alpha-1A receptors only and have less effect on BP because they are more selective.

    Mechanism of Action of Alpha-adrenergic antagonists

  • 29

    Pharmacokinetics for Alpha-adrenergic antagonists

    Well absorbed by oral administration. Doxazosin, Afluzosin, Tamsulosin, and Silodosin are metabolized through the cytochrome P450 system. Silodosin is a substrate for P-glycoprotein. Terazosin is metabolized by the liver but not through the CYP system. The half-life is 8-22 hours with a peak of 1-4 hours

  • 30

    Contraindications for Silodosin

    Severe Renal Dysfunction

  • 31

    Adverse Drug Effects of Alpha-adrenergic antagonists

    Dizziness, fatigue, nasal congestion, headache, drowsiness, orthostatic hypotension. Drugs that are selective for its receptor have an increased incidence of retrograde ejaculation or the ability to ejaculate. “Floppy Iris Syndrome” during cataract eye surgery.

  • 32

    Drugs that inhibit CYP3A4 and CYP2D6 (Verapamil and Dilitazem) may increase plasma concentrations of _______.

    Doxazosin, Alfuzosin, Tamsulosin, and Silodosin

  • 33

    Drugs that induce the CYP450 system (Carbamazepin, Phenytoin, and St. John’s Wart) may _____.

    Decrease plasma concentrations of Alpha-adrenergic antagonists

  • 34

    _______ may prolong QT interval so use caution with other drugs that prolong QT interval (class III anti-arrhythmics).

    Alfuzosin

  • 35

    Drugs that inhibit _____may increase Silodosin concentrations

    P-gp (cyclosproine)

  • 36

    ______should be administered with food. _______should be taken without food.

    Tamsulosin, Alfuzosin, and Silodosin; Doxazosin and Terazosin

  • 37

    ______ requires dosage adjustment in renal impairment

    Silodosin

  • 38

    5 alpha-reductase inhibitors

    Finasteride and Dutasteride

  • 39

    Mechanism of Action for 5 alpha-reductase inhibitors

    Inhibition of 5 alpha-reductase which converts testosterone to dihydrotestosterone (DHT). DHT is an androgen that stimulates prostate growth. By reducing DHT, the prostate shrinks, and urine flow improves, but in order to be effective the prostate must be enlarged. It takes several months for the drug to be effective. Both drugs can also treat alopecia.

  • 40

    Pharmacokinetis of 5 alpha-reductase inhibitors

    These drugs can be taken with food. Both drugs are highly protein bound and metabolized by the CYP450 system. The mean plasma elimination half-life of Finasteride is 6-16 hours, while the terminal elimination half-life of Dutasteride is 5 weeks once steady-state is achieved (typically after 6 months of therapy).

  • 41

    Decreased ejaculate and libido, ED, gynecomastia, and oligospermia. Both drugs are teratogenic can should not be handled by women of childbearing age or who are pregnant. Although they are metabolized by the CYP450 system, drug interactions are rare. Not recommended to use these drugs with testosterone since they inhibit conversion of testosterone to DHT.

    Adverse Drug Effects of 5 alpha-reductase inhibitors

  • 42

    Should be taken with alpha-blockers to relieve symptoms, and both drugs are available in a combo with an alpha-blocker

    5 alpha-reductase inhibitors

  • 43

    What produces the greatest reduction in BPH symptoms?

    Comination therapy (5-alpha reductase inhibitor + alpha-adrenergic antagonists)

  • 44

    A 68-year old man presents to his physician with complaints of inability to maintain an erection during sexual intercourse. He is diagnosed with ED and started on PDE-5 inhibitor. What is the mechanism of action in the treatment of ED?

    Block the degredation of cGMP in the corpus cavernosum

  • 45

    A patient who is taking a PDE-5 inhibitor for ED is diagnosed with angina. Which of the following antianginal medications would be of particular concern in this patient?

    Nitroglycerin

  • 46

    Which of the following statements most accurately describes Alprostadil in the treatement of ED?

    Used as an alternative for patients who are not candidates for oral therapies for ED

  • 47

    Which of the following enzymes or receptors does Tamsulosin block to aid in the treatment of BPH?

    Alpha-(a1) receptor

  • 48

    A patient is worried about starting a new medication to treat BPH beause he is very sensitive to side effects of medications. Which of the following alpha-1-adrenergic antagonists could be recommended because of a lower incidence of systemic side effects?

    Silodosin

  • 49

    A 74-year old patient presents to his PCP to discuss treatment for ED. His current medications include furosemide, isosorbide dinitrate, lisinopril, metformin, and metoprolol succinate. Which of the following would be the safest option for his ED?

    Alprostadil

  • 50

    A patient with BPH has been taking Finasteride for 6 weeks. He reports no improvement in symptoms of urinary frequency, hesitancy, and urgency. On physical exam, it is deterimined that his prostate is significantly enlarged. Which of the following is the best recommendation for this patient?

    Start Tamsulosin and continue Finasteride

  • 51

    A 70-year old man with BPH and has enlarged prostate continues to have urinary symptoms after an adequate trial of Tamsulosin. He is diagnosed with ED. Which medication can be used to treat both BPH and ED in this patient?

    Tadalafil

  • 52

    A patient who is currently being treated for ED with Tadalafil tells the physician that the medication takes too long to work. As such, he would like an alternative that has a faster onset of action. Which of the following PDE-5 inhibitors would be the most appropriate alternative of this patient?

    Avanafil

  • 53

    Which of the following is the CORRECT mechanism of action for Finasteride?

    Inhibits 5-alpha-reductase

  • 54

    Which agent [s] has/have a low likelihood of causing CV adverse effects in a patient with BPH who is also taken meds for HTN? 1. Alfuzosin [Uroxatrol] 2. Tamulosin [Flomax] 3. Finasteride [Proscar]

    2 and 3

  • 55

    Stimulation of muscarinic cholinergic receptors in the bladder muscle may be responsible for:

    Urge incontinence and bladder overactivity

  • 56

    Which of the following drugs in most appropriate for managing incontinence related to bladder overactivity?

    Oxybutynin

  • 57

    Which of the following distinguishes the phosphodiesterase type 5 [PDE-5] inhibitor Tadalafil [Cialis] from the other inhibitors Sildenafil [Viagra] and Vardenafil [Levitra]?

    Duration of Action

  • 58

    Which of the following is NOT a desired characteristic of a therapy for ED?

    Leads to a prolonged erection [>4 hours]

  • 59

    What is the MOA of the PDE-5 inhibitors?

    Enhance effect of nitric oxide

  • 60

    Your patient is taking a PGE-5 inhibitor for ED—he is diagnosed with angina. Which of the following medications would be of particular concern in this man?

    Isosorbide

  • 61

    Which of the following is TRUE regarding Finasteride [Proscar]?

    Associated with birth defects

  • 62

    Your patient is concerned about starting Terazosin because he is very sensitive to side effects of medications. Which of the following adverse effects would be most expected in this patient?

    Dizziness

  • 63

    Your patient is a 62 y/o female with UI, 6 weeks ago she began estrogen vaginal cream at bedtime and Kegel exercises—she says she is no better. She states she leaks whenever she is doing any activity—none when seated or recumbent. She has a history of HTN and she takes HCTZ to control her BP. What kind of UI are you treating?What is the most appropriate next step? What is the most important third step?

    Stress incontinence; Refer to urologist for biofeedback to assist with Kegel exercises; Refer to urologist for consideration of periurethral bulking agents

  • 64

    Doses of _____may need to be reduces in the presence of potent inhibitors of CYP34A (clarithromycin and ritonavir)

    PDE-5 Inhibitors

  • 65

    It is not ideal to use 5-Alpha Reductase Inhibitors with _____?

    Testosterone because the drugs inhibit the conversion of testosterone to DHT

  • 66

    Should be avoided in severe hepatic impairment

    PGE-5 Inhibitors

  • 67

    Verapamil and Dilitazem may increase plasma concentrations of _______.

    Doxazosin, Alfuzosin, Tamsulosin, and Silodosin

  • 68

    Carbamazepin, Phenytoin, and St. John’s Wart may _____.

    Decrease plasma concentrations of Doxasozin, Alfuzosin, Tamulosin, and Silodosin